Consequently, prolactin levels below 162 mU/L (7.6 ng/mL) at withdrawal are still regarded as the goal of long-term cabergoline treatment and, together with maximum tumor size below 3.1 mm, predict remission of prolactin-secreting tumors in the highest percentage of patients [2]. The gene discussed is PRL; the disease is neoplasm.